Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)
Phase of Trial: Phase I/II
Latest Information Update: 17 Dec 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms BOOSTER MELANOMA
- 06 Dec 2018 Planned number of patients changed from 125 to 120.
- 06 Dec 2018 Status changed from not yet recruiting to recruiting.
- 30 Nov 2017 New trial record